KRAS: feeding pancreatic cancer proliferation.

Oncogenic KRAS mutation is the signature genetic event in the progression and growth of pancreatic ductal adenocarcinoma (PDAC), an almost universally fatal disease. Although it has been appreciated for some time that nearly 95% of PDAC harbor mutationally activated KRAS, to date no effective treatments that target this mutant protein have reached the clinic. A number of studies have shown that oncogenic KRAS plays a central role in controlling tumor metabolism by orchestrating multiple metabolic changes including stimulation of glucose uptake, differential channeling of glucose intermediates, reprogrammed glutamine metabolism, increased autophagy, and macropinocytosis. We review these recent findings and address how they may be applied to develop new PDAC treatments.

[1]  Weidong Zhou,et al.  Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. , 2012, Journal of proteome research.

[2]  F. Ismail-Beigi,et al.  Regulation of glut1 mRNA by Hypoxia-inducible Factor-1 , 2001, The Journal of Biological Chemistry.

[3]  P. Bastiaens,et al.  Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling , 2013, Nature.

[4]  E. Lapi,et al.  Autophagic activity dictates the cellular response to oncogenic RAS , 2012, Proceedings of the National Academy of Sciences.

[5]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[6]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[7]  D. Bar-Sagi,et al.  Differential Activation of the Rac Pathway by Ha-Ras and K-Ras* , 2001, The Journal of Biological Chemistry.

[8]  M. Kojima,et al.  Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome , 2008, Cancer science.

[9]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[10]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[11]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[12]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[13]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[14]  William A Weiss,et al.  Principles and Current Strategies for Targeting Autophagy for Cancer Treatment , 2011, Clinical Cancer Research.

[15]  R. Goody,et al.  The pre-hydrolysis state of p21(ras) in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins. , 1999, Structure.

[16]  F. Chiaradonna,et al.  Acquired glucose sensitivity of k-ras transformed fibroblasts. , 2005, Biochemical Society transactions.

[17]  C. Der,et al.  Ras history , 2010, Small GTPases.

[18]  Scott E. Kern,et al.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.

[19]  N. Curthoys,et al.  Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). , 2007, The Biochemical journal.

[20]  H. Eagle,et al.  Nutrition needs of mammalian cells in tissue culture. , 1955, Science.

[21]  J. Kleeff,et al.  Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels , 2013, Front. Physiol..

[22]  J. McCarter,et al.  STK33 kinase activity is nonessential in KRAS-dependent cancer cells. , 2011, Cancer research.

[23]  Y. Kloog,et al.  A unique platform for H-Ras signaling involving clathrin-independent endocytosis. , 2007, Molecular biology of the cell.

[24]  Gregory Stephanopoulos,et al.  Molecular Systems Biology Peer Review Process File Oncogenic K-ras Decouples Glucose and Glutamine Metabolism to Support Cancer Cell Growth Transaction Report , 2022 .

[25]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[26]  M. Lotze,et al.  The Beclin 1 network regulates autophagy and apoptosis , 2011, Cell Death and Differentiation.

[27]  Gregory Stephanopoulos,et al.  The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4 , 2013, Cell.

[28]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[29]  Ralph J DeBerardinis,et al.  Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.

[30]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[31]  G. Ferbeyre,et al.  Mitochondrial Dysfunction Contributes to Oncogene-Induced Senescence , 2009, Molecular and Cellular Biology.

[32]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[33]  Daniel J Klionsky,et al.  Mammalian autophagy: core molecular machinery and signaling regulation. , 2010, Current opinion in cell biology.

[34]  I. Mellman,et al.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.

[35]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[36]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[37]  J. Kleeff,et al.  Energy metabolism and proliferation in pancreatic carcinogenesis , 2012, Langenbeck's Archives of Surgery.

[38]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[39]  J. Matés,et al.  Oxidative stress in apoptosis and cancer: an update , 2012, Archives of Toxicology.

[40]  Christian M. Metallo,et al.  Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells , 2013, Nature.

[41]  H. Coller,et al.  Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.

[42]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[43]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[44]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[45]  N. Amariglio,et al.  Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. , 2005, Cancer research.

[46]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[47]  Malte Buchholz,et al.  Stromal biology and therapy in pancreatic cancer , 2010, Gut.

[48]  A. Koong,et al.  Pancreatic tumors show high levels of hypoxia. , 2000, International journal of radiation oncology, biology, physics.

[49]  Marta Cascante,et al.  K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts , 2005 .

[50]  D. Bar-Sagi,et al.  Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. , 1986, Science.

[51]  F. Oswald,et al.  CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in-vivo and in-vitro models , 2009 .

[52]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[53]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[54]  A. Kimmelman,et al.  The dynamic nature of autophagy in cancer. , 2011, Genes & development.

[55]  J. Grem,et al.  Metabolism and action of amino acid analog anti-cancer agents. , 1990, Pharmacology & therapeutics.

[56]  G. Semenza.  HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[57]  D. Vocadlo,et al.  Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells , 2011, Nature chemical biology.

[58]  A. Thorburn,et al.  Autophagy in cancer: good, bad, or both? , 2006, Cancer research.

[59]  Marc Liesa,et al.  Pancreatic cancers require autophagy for tumor growth. , 2011, Genes & development.

[60]  Yongqiang Chen,et al.  The regulation of autophagy – unanswered questions , 2011, Journal of Cell Science.

[61]  R. Tomasini,et al.  Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[62]  E. Racker,et al.  Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Seamus J. Martin,et al.  Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. , 2011, Molecular cell.

[64]  C. Dang,et al.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.

[65]  Simon Tavaré,et al.  Autophagy mediates the mitotic senescence transition. , 2009, Genes & development.

[66]  Jiro Shimada,et al.  In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction , 2013, Proceedings of the National Academy of Sciences.

[67]  L. Alberghina,et al.  Ras-dependent carbon metabolism and transformation in mouse fibroblasts , 2006, Oncogene.

[68]  Linda C Hsieh-Wilson,et al.  Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism , 2012, Science.

[69]  J. Matés,et al.  Glutamine homeostasis and mitochondrial dynamics. , 2009, The international journal of biochemistry & cell biology.

[70]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma. , 2006, Genes & development.

[71]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[72]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[73]  Chi V Dang,et al.  Links between metabolism and cancer. , 2012, Genes & development.

[74]  Nathan T. Ross,et al.  STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability , 2012, Proceedings of the National Academy of Sciences.

[75]  A. Khandoker,et al.  Cardiac rehabilitation outcomes following a 6-week program of PCI and CABG Patients , 2013, Front. Physiol..

[76]  E. White,et al.  Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids , 2013, Proceedings of the National Academy of Sciences.

[77]  K. Lim,et al.  Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. , 2005, Cancer cell.

[78]  Qi Sun,et al.  Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. , 2012, Angewandte Chemie.

[79]  Eileen White,et al.  Autophagy and Metabolism , 2010, Science.

[80]  D. Vocadlo,et al.  Hyper-O-GlcNAcylation Is Anti-apoptotic and Maintains Constitutive NF-κB Activity in Pancreatic Cancer Cells* , 2013, The Journal of Biological Chemistry.